# Multi-Omics Integration Progress Summary

## ✅ Completed Steps

### 1. Gene Annotation (COMPLETE)
- **Annotated blood dataset genes** with Gene_Symbol, Entrez_ID, and Gene_Name
- **Files processed:**
  - `gse159610_substantial_fc_genes.tsv` → 4,024 genes annotated (93.9%)
  - `gse159610_top_candidate_genes.tsv` → 95 genes annotated (95.0%)
  - `gse159610_full_de_results.tsv` → 13,615 genes annotated (95.3%)
- **Output:** Annotated files with `_annotated.tsv` suffix

### 2. Multi-Omics Integration (COMPLETE)
- **Integrated datasets:**
  - Blood transcriptomics (GSE159610): 100 genes
  - Tissue transcriptomics (GSE122897): 10 genes
  - GWAS integration: 1,010 genes
  - Pathway enrichment: Multiple pathways identified
- **Total unique genes analyzed:** 110
- **GWAS support:** 11 genes (10.0%) now properly matched using Entrez_ID
- **Output files:**
  - `multi_omics_comprehensive_prioritized_genes.tsv` - Full integration
  - `multi_omics_prioritized_top50.tsv` - Top 50 genes
  - `multi_omics_blood_specific_genes.tsv` - Blood-specific candidates
  - `multi_omics_tissue_specific_genes.tsv` - Tissue-specific candidates
  - `multi_omics_prioritization_report.txt` - Summary report

### 3. Pathway Enrichment (COMPLETE)
- **Analyzed top 50 prioritized genes**
- **Enriched pathways found:**
  - FDR < 0.05: 4 pathways
  - FDR < 0.1: 4 pathways
  - FDR < 0.2: 7 pathways
- **Top pathways:**
  1. **Collagen-containing extracellular matrix** (GO:CC) - p=0.014, 3 genes
  2. **Basement membrane** (GO:CC) - p=0.034, 2 genes
  3. **Extracellular matrix** (GO:CC) - p=0.039, 3 genes
- **Output files:**
  - `pathway_enrichment_prioritized_fdr_0.05.tsv`
  - `pathway_enrichment_prioritized_fdr_0.1.tsv`
  - `pathway_enrichment_prioritized_fdr_0.2.tsv`
  - `pathway_enrichment_prioritized_summary.tsv`

## 🎯 Top Prioritized Genes

### Top 10 Multi-Omics Prioritized Genes:

1. **CPXM2** (Score: 14.4)
   - Tissue Log2FC: -2.07
   - GWAS support: Yes
   - Function: Carboxypeptidase X, M14 family member 2

2. **Ccd** (Score: 13.0)
   - Tissue Log2FC: 2.88
   - Function: Cleidocranial dysplasia

3. **MARCO** (Score: 12.6)
   - Tissue Log2FC: 2.61
   - GWAS support: Yes
   - Function: Macrophage receptor with collagenous structure

4. **CABCOCO1** (Score: 12.3)
   - Tissue Log2FC: -2.22
   - GWAS support: Yes
   - Function: Ciliary associated calcium binding coiled-coil 1

5. **SIGLEC1** (Score: 10.9)
   - Blood Log2FC: 2.24
   - GWAS support: Yes
   - Function: Sialic acid binding Ig like lectin 1

6. **TGFBI** (Score: 10.1)
   - Tissue Log2FC: 1.77
   - GWAS support: Yes
   - Function: Transforming growth factor beta induced

7. **LAMA3** (Score: 10.0)
   - Tissue Log2FC: -1.48
   - GWAS support: Yes
   - Function: Laminin subunit alpha 3

8. **CDC14C** (Score: 10.0)
   - Blood Log2FC: 2.06
   - Function: Cell division cycle 14C

9. **LOC105374059** (Score: 10.0)
   - Blood Log2FC: -2.89
   - Function: Uncharacterized LOC105374059

10. **MIR124-1HG** (Score: 10.0)
    - Blood Log2FC: -4.36
    - Function: MIR124-1 host gene

## 📊 Key Findings

### Dataset Coverage
- **Blood (GSE159610):** 100 genes (90.9%)
- **Tissue (GSE122897):** 10 genes (9.1%)
- **GWAS support:** 11 genes (10.0%)
- **Pathway enrichment:** Extracellular matrix pathways enriched

### Biological Insights
1. **Extracellular Matrix Remodeling:** Top enriched pathways involve ECM components
   - Collagen-containing ECM
   - Basement membrane
   - Suggests structural changes in aneurysm tissue

2. **Multi-Omics Validation:**
   - 6 genes with GWAS support in top 10
   - Tissue and blood signatures both contribute
   - Cross-validation across datasets

3. **Gene Categories:**
   - **Structural proteins:** CPXM2, MARCO, LAMA3, TGFBI
   - **Immune/inflammatory:** SIGLEC1, MARCO
   - **Non-coding RNA:** MIR124-1HG
   - **Cell cycle:** CDC14C

## 🔄 Next Steps

### Immediate (In Progress)
1. ✅ Pathway enrichment - **COMPLETE**
2. ⏳ Create visualizations for integration results
3. ⏳ Annotate top genes with literature

### Short-term (Next 1-2 days)
4. Build prediction model using prioritized genes
5. Risk stratification analysis
6. SHAP interpretation for model features

### Medium-term (Next week)
7. Polygenic Risk Score development
8. Endothelial dysfunction analysis
9. Complete multi-omics model training

## 📁 Output Files Generated

### Integration Results
- `results/multi_omics_comprehensive_prioritized_genes.tsv`
- `results/multi_omics_prioritized_top50.tsv`
- `results/multi_omics_blood_specific_genes.tsv`
- `results/multi_omics_tissue_specific_genes.tsv`
- `results/multi_omics_prioritization_report.txt`

### Pathway Enrichment
- `results/pathway_enrichment_prioritized_fdr_0.05.tsv`
- `results/pathway_enrichment_prioritized_fdr_0.1.tsv`
- `results/pathway_enrichment_prioritized_fdr_0.2.tsv`
- `results/pathway_enrichment_prioritized_summary.tsv`

### Annotated Datasets
- `results/gse159610_substantial_fc_genes_annotated.tsv`
- `results/gse159610_top_candidate_genes_annotated.tsv`
- `results/gse159610_full_de_results_annotated.tsv`

## 🎯 Success Metrics

- ✅ **Gene annotation:** 95%+ success rate
- ✅ **GWAS matching:** 10% of prioritized genes have GWAS support
- ✅ **Pathway enrichment:** ECM pathways identified (clinically relevant)
- ✅ **Multi-omics integration:** 110 genes prioritized across datasets
- ⏳ **Model performance:** To be determined (target: AUC 0.85-0.92)

---

**Last Updated:** Based on completed integration and pathway enrichment analysis
**Status:** Multi-omics integration foundation complete, proceeding to visualization and modeling


